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Methods: Consensus statements about PCAwere developed through a detailed literature review, the
formation of an international multidisciplinary working party which convened on four occasions, and
a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA.
Results: A three-level classification framework for PCA is described comprising both syndrome-
and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and
neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification
level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core
features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attribut-
able to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD],
prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the
PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional
syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome
severity and characterizing phenotypic heterogeneity within the PCA spectrum.
Discussion: There was strong agreement regarding the definition of the core clinico-radiological
syndrome, meaning that the current consensus statement should be regarded as a refinement, devel-
opment, and extension of previous single-center PCA criteria rather than any wholesale alteration or
redescription of the syndrome. The framework and terminology may facilitate the interpretation of
research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral
interventions, pharmacological trials), and provide a foundation for future collaborative work.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).203
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2391. Introduction
The term posterior cortical atrophy (PCA) was coined by
D. Frank Benson and colleagues to describe a series of pa-
tients with early visual dysfunction in the setting of neurode-
generation of posterior cortical regions [1] (Fig. 1). The PCA
syndrome aligned with several other reports of patients
with similar progressive loss of higher visual function
(e.g., [2–12]). PCA typically presents in the mid-50s or early
60s with a variety of unusual visuoperceptual symptoms,
such as diminished ability to interpret, locate, or reach for
objects under visual guidance; deficits in numeracy, literacy,
and praxis may also be apparent. Although episodic memory
and insight are initially relatively preserved, progression of
PCA ultimately leads to a more diffuse pattern of cognitive
dysfunction.
Several single-center groups of researchers have proposed
diagnostic criteria for the syndrome [13,14] or detailed
inclusion criteria for individual studies (e.g., [15–17]).
PCA has also been recognized and described in consensus
criteria for typical and atypical Alzheimer’s disease
[18,19]. These existing criteria have reasonable consistency
and have proved useful in many clinical and research
contexts.
However, the extant detailed descriptions of PCA are
based on clinical experience at single centers and have not
been deliberated or validated more widely. Present-day
PCA criteria were also formulated before the development
of Alzheimer’s disease (AD) pathophysiological bio-
markers, and although recent AD criteria include PCA, theFLA 5.4.0 DTD  JALZ2350_proofclinical phenotype is not described in detail and such criteria
naturally do not encompass individuals with the PCA syn-
drome who are negative for AD pathophysiological bio-
markers. Some inconsistencies exist among the core
features described, with the Tang-Wai but not Mendez
criteria excluding individuals with early Parkinsonism or
hallucinations, while Mendez but not Tang-Wai stipulates
the relative preservation of verbal fluency [13,14]. Such
inconsistencies are mirrored explicitly or implicitly in the
application of terminology, with the term PCA sometimes
being used as a descriptive clinical (syndrome level) term
and sometimes as a diagnostic (disease level) label. For
example, some researchers consider PCA primarily or
solely as an atypical form of AD (the “visual variant of
AD,” e.g., [20]), whereas others cite neuropathological evi-
dence demonstrating that multiple pathologies can underlie
the PCA syndrome (e.g., [15]). Inconsistency of terminology
and usage likely reflects in part the interests or requirements
of different investigators or research contexts. For example,
syndromic classification is likely to be entirely appropriate
for studies exploring behavioral interventions, whereas clin-
ical trials of disease-specific pharmacological agents may
additionally require consideration of the underlying molec-
ular pathology. In the absence of criteria that clearly reflect
this potential diversity of use, it remains unclear whether
individuals with PCA should be included or excluded from
conventional clinical trials for AD (e.g., owing to the poten-
tial unsuitability of the associated interventions, biomarkers,
and/or outcome measures). Cons Qequently, individuals 1 March 2017  4:01 pm  ce
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Fig. 1. Single-participant axial images for one control participant and one patient with PCA showing cerebral blood flow (ASL), glucose metabolism (FDG-
PET), atrophy (structural magnetic resonance imaging), and amyloid deposition (florbetapir-PET). For clinical purposes, 18F-florbetapir images should be read
on a gray scale. Abbreviations: ASL, arterial spin labeling; CBF, cerebral blood flow; FDG-PET, 18F-labeled fluorodeoxyglucose positron emission tomography;
PCA, posterior cortical atrophy; SUVR, standard uptake value ratio. Adapted from Lehmann et al., 2016, Figure 1.
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361affected by PCA risk are being unable to access potentially
helpful interventions owing to a lack of evidence regarding
their effectiveness. Conversely, if criteria require evidence
for AD pathology, individuals with PCA due to other causes
may not be considered for behavioral interventional trials
from which they may benefit. Finally, existing criteria pro-
vide an inadequate foundation from which to proceed with
future studies exploring the factors influencing phenotypic
heterogeneity and disease progression, acquiring evidence
linking clinical phenotype to underlying pathology.
2. Aims
The present study describes the formation and delibera-
tions of a PCA working party that aimed to establish a
consensus opinion regarding the PCA syndrome. The goal
of the work was to review, revise, and complement existing
single-center diagnostic criteria to represent multidisci-
plinary and multicenter experience and knowledge. In lightFLA 5.4.0 DTD  JALZ2350_proofof the problems outlined previously and the challenges fac-
ing the PCA research field, a multilevel PCA classification
framework is proposed for use in a number of different
research contexts.
3. Methods
Following a detailed review of the literature (S.J.C., M.L.,
J.M.S., G.D.R., M.N.R., and N.C.F. [21]), a PCA Working
Party of experienced clinicians and researchers formed to
develop a consensus statement regarding research criteria
for PCA. Representatives of the group met at the Alz-
heimer’s Association International Conferences in Vancou-
ver (July 2012; see [22]) and Boston (July 2013). An
Atypical Alzheimer’s Disease and Associated Disorders Pro-
fessional Interest Area (PIA) was subsequently constituted
subsequently under the auspices of the International Society
to Advance Alzheimer’s Research and Treatment. In June
2014, an online survey of Working Party and PIA members 1 March 2017  4:01 pm  ce
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447was conducted. Participants were requested to estimate the
frequency of symptoms, signs, and features (never seen
[0%], rare [0%–25%], common [25%–75%], very frequent
[75%–100%], always present [100%]). Participants were
also asked to rate their level of agreement with a series of
statements regarding the conceptualization of PCA (Likert
scale: 15 strongly disagree, through to 75 strongly agree).
The survey was completed by 36 experienced group mem-
bers with backgrounds in neurology, psychology, pathology,
psychiatry, gerontology, and neuroscience (years since
qualification: mode and median: 20–30 years, range:
1–.30 years; number of individuals with PCA encountered:
median: 20–30, mode: 30–50, range: 1–.50). The results of
the survey (see Fig. 2) and their implications for a consensus
statement were discussed at the next PIA meeting (AAIC,
Copenhagen, July 2014). The consensus statement was sub-
sequently drafted (S.J.C.) and developed with a small group
of experts (N.C.F., J.M.S., G.D.R., W.M.v.d.F., M.M.,
B.C.D., R.V., and J.S.S.), and a revised version circulated
to the PCA Working Party and selected PIA members for
their detailed feedback before final discussion and agree-
ment (AAIC, Washington, July 2015). The final version
was approved by all authors.448
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4744. Classification framework
A three-level classification framework for PCA is
described in Fig. 3. Level 1 establishes that the presenting
problem has a neurodegenerative basis and a posterior
cortical focus, based on the identification of the core clinical
and cognitive features that define the PCA syndrome, plus
supportive neuroimaging evidence if available. Further
core features include evidence of insidious onset and gradual
progression. Exclusion criteria include evidence of a brain
tumor or other mass lesion, significant vascular disease
including focal stroke, primary ocular disease, or other iden-
tifiable causes for cognitive impairment, but only where
independently sufficient to explain the clinical and cognitive
syndrome. Level 2 establishes whether the presentation is
one of pure PCA or whether the patient meets the core
criteria for both the PCA syndrome and an additional neuro-
degenerative syndrome (in the absence of biomarkers). Level
3 involves a more formal determination of the underlying
cause of the PCA syndrome, based on pathophysiological
biomarker evidence. Levels 1 and 2 yield a syndrome-level
description of the presenting complaint. Level 3 yields a
disease-level description. Levels 1–3 are outlined in greater
detail in the following.475
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4834.1. Classification level 1: The core features of the PCA
syndrome
As defined in the perspective article which followed the
first consensus meeting, “PCA is a clinico-radiological syn-
drome characterized by progressive decline in visual pro-
cessing and other posterior cognitive functions, relativelyFLA 5.4.0 DTD  JALZ2350_proofintact memory and language in the early stages, and atrophy
of posterior brain regions” ([23], p. 463). The core clinical,
cognitive, and (optional supportive) neuroimaging features
and exclusion criteria for PCA are listed in Table 1. These
early or presenting features are listed in order of (descend-
ing) frequency at first assessment in line with the quantita-
tive ratings provided by online survey participants (see
Fig. 2). The list of cognitive features is a summation of all
features listed in Mendez et al. [13] and Tang-Wai et al. [14].
The clinical and exclusion criteria constrain the definition
of PCA to individuals with a neurodegenerative condition.
The semi-arbitrary stipulation of three or more cognitive fea-
tures is designed to ascertain evidence of a cluster of poste-
rior cognitive deficits and reduce misclassifications based on
overinterpretation of a single complaint or abnormal test
score. The stringency of this stipulation is also mitigated
by the extensive list of potential features which fall broadly
into the domains of basic visual, visuoperceptual, visuospa-
tial, literacy, numeracy, praxis, and higher sensory functions.
Many of these posterior cognitive deficits may have a pro-
nounced impact on activities of daily living.
A critical element of the PCA cognitive profile is the
contrast between the posterior cortical dysfunction and the
relative sparing of other cognitive domains. This is aimed
at distinguishing PCA from typical (amnestic) AD (episodic
memory), logopenic-variant primary progressive aphasia
(lvPPA; language), frontotemporal dementia and the AD
phenotype variously labeled frontal variant AD, behavioral
variant AD, or dysexecutive AD (which primarily manifests
as impairments of executive functions, behavior, and person-
ality). The concept of “relative sparing” is intentionally flex-
ible to accommodate different assessment settings and tools.
Operationalizing these criteria with recommended sets of
brief and detailed cognitive tasks is a future objective of
the working group, but the main principle is to reduce the
impact of core deficits on assessment of these functions.
For example, accurate testing of anterogradememory in peo-
plewith PCA requires tests that avoid not only explicit visual
demands (e.g., Rey–Osterrieth figure copy) but alsomore im-
plicit visual demands on visually mediated processes such as
mental imagery (e.g., verbal paired associate learning).
The neuroimaging features of PCAare intentionally broad
to reflect the loose anatomical description of “posterior
cortical atrophy,” with theworking group regarding evidence
of focal structural (e.g., atrophy on magnetic resonance
imaging) or functional (e.g., hypometabolism on 18F-labeled
fluorodeoxyglucose positron emission tomography or single-
photon emission computed tomography) abnormality in the
occipital, parietal, and/or occipito-temporo-parietal cortices
as supportive of the clinico-radiological syndrome. The
inclusion of neuroimaging evidence of posterior cortical
atrophy or dysfunction as an optional, supportive feature
rather than obligatory component of the syndrome-level
description is consistent with previous criteria. This issue
generated considerable debate, but maintaining the optional
status was justified on both clinical (e.g., variable extent of 1 March 2017  4:01 pm  ce
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Fig. 2. Mean and standard error ratings of clinical presentation features, symptoms, and signs in PCA, as rated by experts in the online survey. Abbreviation:
PCA, posterior cortical atrophy.
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692atrophy at presentation) and practical grounds (e.g., accessi-
bility of neuroimaging facilities; not wishing to exclude
patients unable to undergo M.R. investigation from all
PCA-related research). Where for practical reasons neuroi-
maging evidence cannot be obtained, research studies should
specify the evidence used to support the classification of
PCA. Another issue is that individuals with the visual variant
of Creutzfeldt–Jakob disease typically decline rapidly
such that obvious focal atrophy is not easily demonstrated
[24–26]. We debated the utility of classifying such
individuals within the PCA framework, which may only be
appropriate for prion disease patients with an insidious
(rather than rapid) progression ([15], subject [20,27]). It
should also be noted that evidence provided by more
recently established molecular imaging techniques is
incorporated together with other in vivo biomarkers in the
disease-level description (see classification level 3).
The clinical, cognitive, and exclusion criteria (discussion
of neuroimaging criteria mentioned previously) are largely
consistent with existing single-center definitions of the syn-
drome [13,14]. Working group discussions elicited broad
agreement regarding the specific features that constitute
PCA and there was a strong reluctance to radically alter
preceding descriptions of the syndrome, which has becomeFig. 3. Diagnostic process and PCA classification. Key diagnostic questions at
levels 1 and 2) are lightly shaded and disease-level descriptions (classification lev
and PCA-prion (solid ovals) are distinguished from PCA-LBD and PCA-CBD (d
biomarkers. Other disease-level classifications may be appropriate (e.g., a patient w
ipated (e.g., PCA attributable to GRNmutations). The thickness of lines connecting
common cause of PCA. Abbreviations: AD, Alzheimer’s disease; CBD, corticobas
tbc, to be confirmed.
FLA 5.4.0 DTD  JALZ2350_proofa well-established clinical concept. Nonetheless, one point
of note is the primacy given to visual impairment in the
earlier criteria (Mendez et al: “Presentation with visual com-
plaints with intact primary visual functions”; Tang-Wai et al:
“Presentation of visual complaints in the absence of signifi-
cant primary ocular disease explaining the symptoms”
[13,14]). In the proposed consensus statement, this
criterion is broadened to “Prominent early disturbance of
visual plus/minus other cognitive functions with a
presumed posterior location.” This reflects the position of
65% of the online survey group who agreed (compared
with 15% disagreeing and 20% neither agreeing nor
disagreeing) with the statement “Progressive focal
disorders of nonvisual posterior cognitive functions (e.g.,
apraxia, agraphia, acalculia) can also be classified as PCA
in some research contexts.” The Qworking group rejected
further broadening of the criterion to “Prominent early
disturbance of visual and/or other posterior cognitive
functions” on the basis that (1) removal of the visual
criterion might lead to unhelpful diagnostic confusion
between PCA and CBS, lvPPA and other syndromes, (2)
very detailed neuropsychological testing of patients
presenting with focal posterior nonvisual complaints
typically uncover evidence of subtle impairments in visualeach level are shown in boxes. Syndrome-level descriptions (classification
el 3) are darkly shaded. Among the disease-level classifications, PCA-AD
ashed ovals) owing to the current availability of in vivo pathophysiological
ith PCA plus visual hallucinations may have LBD-variant of AD) or antic-
classification levels 2 and 3 is intended to reflect the status of AD as themost
al degeneration; LBD, Lewy body disease; PCA, posterior cortical atrophy;
 1 March 2017  4:01 pm  ce
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Table 1
Core features of the PCA clinico-radiological syndrome (classification level 1)
Clinical, cognitive, and neuroimaging features are rank ordered in terms of (decreasing) frequency at first assessment as rated by online survey participants
(see Appendix 1 Q11).
Clinical features:
Insidious onset
Gradual progression
Prominent early disturbance of visual 6 other posterior cognitive functions
Cognitive features:
At least three of the following must be present as early or presenting features 6 evidence of their impact on activities of daily living:
Space perception deficit
Simultanagnosia
Object perception deficit
Constructional dyspraxia
Environmental agnosia
Oculomotor apraxia
Dressing apraxia
Optic ataxia
Alexia
Left/right disorientation
Acalculia
Limb apraxia (not limb-kinetic)
Apperceptive prosopagnosia
Agraphia
Homonymous visual field defect
Finger agnosia
All of the following must be evident:
Relatively spared anterograde memory function
Relatively spared speech and nonvisual language functions
Relatively spared executive functions
Relatively spared behavior and personality
Neuroimaging:
Predominant occipito-parietal or occipito-temporal atrophy/hypometabolism/hypoperfusion on MRI/FDG-PET/SPECT
Exclusion criteria:
Evidence of a brain tumor or other mass lesion sufficient to explain the symptoms
Evidence of significant vascular disease including focal stroke sufficient to explain the symptoms
Evidence of afferent visual cause (e.g., optic nerve, chiasm, or tract)
Evidence of other identifiable causes for cognitive impairment (e.g., renal failure)
Abbreviations: PCA, posterior cortical atrophy; MRI, magnetic resonance imaging; FDG-PET, 18F-labeled fluorodeoxyglucose positron emission tomog-
raphy; SPECT, single-photon emission computed tomography.
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832cognition (see Fig. 4), and (3) some “nonvisual” complaints
may be partly rooted in visual dysfunction (e.g., writing im-
pairments partly attributable to disordered mental imagery
for letters).833
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8494.2. Classification level 2: Pure PCA and PCA with
additional features (PCA-plus)
In classification level 2, a division is drawn between indi-
viduals who solely meet the criteria for PCA (PCA-pure)
and individuals who exhibit additional features consistent
with other recognized neurodegenerative syndromes
(PCA-plus). All individuals must fulfill the criteria for the
core clinico-radiological syndrome (level 1), with the
PCA-pure/PCA-plus distinction made on the basis of
nonfulfillment/fulfillment of additional core clinical criteria
for lvPPA, CBS, or another neurodegenerative syndrome
(see Table 2). The cited examples are based on recognized
diagnostic criteria for the clinical syndromes of dementia
with Lewy bodies [28] and CBS [29,30].FLA 5.4.0 DTD  JALZ2350_proofClassification level 2 exists as a buffer zone between a
broad, purely symptomatic definition of PCA (level 1) and
disease-level descriptions of the different clinico-biological
entities (supported by biomarker evidence) which fall under
that syndromic umbrella (level 3). This intermediate classifi-
cation stage is motivated by a combination of in vivo
biomarker and postmortem pathological data, clinical
opinion, and research practicality. In vivo biomarker and
postmortem pathological data from published case series
indicate that the vast majority of reported cases of PCA are
attributable to AD (see [14,15,31–33]). Reflecting such
data, clinical opinion has tended toward regarding PCA
primarily or even solely as an atypical phenotype of AD,
many defining PCA as “the visual posterior variant of AD.”
Accordingly, some working group members questioned
whether features suggestive of non-AD pathologies, such
as hallucinations and cognitive fluctuations suggestive of
the histopathologically defined entity of Lewy body disease
(LBD), should even be incorporated as exclusion criteria in
the core definition of PCA. The PCA-pure/PCA-plus 1 March 2017  4:01 pm  ce
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Fig. 4. Case study of a PCA patient presenting with “nonvisual” symptoms. Abbreviation: PCA, posterior cortical atrophy.
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942distinction permits clinicians or researchers to restrict study
inclusion to a subpopulation who may be more likely to
have AD as the underlying pathology, while at the sameTable 2
Classification of PCA-pure and PCA-plus (classification level 2)
PCA-pure
Individuals must fulfill the criteria for the core clinico-radiological PCA synd
neurodegenerative syndrome.
PCA-plus
Individuals must fulfill the criteria for the core clinico-radiological PCA synd
neurodegenerative syndrome, such as
Dementia with Lewy bodies (DLBs)
Following the diagnostic criteria proposed by theDLB consortium (McKeith
A) or one or more core features (list A) and one or more suggestive feature
A. Core features
 Fluctuating cognition with pronounced variations in attention and
 Recurrent visual hallucinations that are typically well formed and
 Spontaneous features of parkinsonism
B. Suggestive features
 REM sleep behavior disorder
 Severe neuroleptic sensitivity
 Low dopamine transporter uptake in basal ganglia demonstrated b
Corticobasal syndrome (CBS)
Following the modified CBS criteria proposed by Armstrong et al. (2013),
a) limb rigidity or akinesia
b) limb dystonia
c) limb myoclonus
plus 2 of:
d) orobuccal or limb apraxia
e) cortical sensory deficit
f) alien limb phenomena (more than simple levitation)
Possible corticobasal syndrome may be symmetric and requires presentatio
Abbreviations: PCA, posterior cortical atrophy; SPECT, single-photon emissio
FLA 5.4.0 DTD  JALZ2350_prooftime acknowledging the lack of one-to-one correspondence
between syndrome and pathology (e.g., patients fulfilling
PCA and CBS criteria whose impairments are attributableQ12
rome (level 1), and not fulfill core clinical criteria for any other
rome (level 1) and also fulfill core clinical criteria for at least one other
et al., 2005), individualsmust exhibit two ormore core features of DLBs (list
s (list B):
alertness
detailed
y SPECT or PET imaging
a diagnosis of probable CBS requires asymmetric presentation of 2 of
n of 1 of a–c plus 1 of d–f.
n computed tomography; PET, positron emission tomography.
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1067to AD). The PCA-plus classification may also capture indi-
viduals who show additional features owing tomixed pathol-
ogy or moderate to high subcortical vascular burden. Such
debate may be moot in most situations where in vivo bio-
markers are available. However, a full examination of the
relationship between the PCA phenotype and underlying pa-
thologywill require documentation of the fulfillment/nonful-
fillment of both core PCA and additional syndromic criteria.
There are also methodological limitations concerning bio-
markers reflected in variability of results across laboratories
[34,35]. Besides, molecular imaging and cerebrospinal fluid
analysis are not available for all individuals in all centers, and
pathophysiological biomarkers are available for a limited
number of diseases and it is only the diagnostic criteria for
AD and FTD incorporate them. Ultimately, the Working
Party aimed to produce consensus guidelines that have
utility in every research setting. Thus, the concepts PCA-
pure and PCA-plus are advanced as a simple, practicable
method for improving the consistency of inclusion criteria
in studies and refining PCA samples in situations where
biomarker data are not available. Also, International Work-
ing Group criteria (IWG2) [19] do not provide a formal clas-
sification for individuals with a clinical presentation
consistent with PCA in whom in vivo biomarkers are not
available. The intermediate classification of PCA-pure/
PCA-plus is aimed at facilitating the inclusion of participants
in research studies even in the absence of direct evidence of
underlying pathophysiological process. The practical impli-
cation of this formulation is that the concept of PCA-pure or
-plus (level 2)may be largely redundant where biomarker ev-
idence is available, where the expectation would be classifi-
cation at disease-specific level 3 (see the following).Table 3
Diagnostic criteria for disease-level descriptions (classification level 3)
PCA-AD
Following IWG2 (Dubois et al., 2014), the classification of PCA-AD (and, by e
of the PCA syndrome (classification level 1) plus in vivo evidence of Alzheim
 Decreased Ab1–42 together with increased T-tau and/or P-tau in CSF
 Increased tracer retention on amyloid PET
 Alzheimer’s disease autosomal-dominant mutation present (in PSEN1, P
If autopsy confirmation of AD is available, the term definite PCA-AD would
PCA-LBD
Molecular biomarkers for LBD are currently unavailable; therefore, an in vivo d
both classified as PCA-mixed by virtue of fulfilling DLB clinical criteria and
appropriate. If autopsy confirmation of LBD is available, the term definite PCA
appropriate for individuals with mixed or multiple pathologies (e.g., PCA-AD
PCA-CBD
Molecular biomarkers for CBD are currently unavailable; therefore, an in vivo d
both classified as PCA-mixed by virtue of fulfilling CBS criteria and shown to b
If autopsy confirmation of CBD is available, the term definite PCA-CBD wou
PCA-prion
There are a number of promising biomarkers for prion disease (e.g., Orru et a
incorporated into diagnostic criteria. Pending this process, an in vivo diagnosi
available or a known genetic form of prion disease has been determined, the t
Abbreviations: PCA, posterior cortical atrophy; AD, Alzheimer’s disease; CSF
bodies; CBD, corticobasal degeneration.
FLA 5.4.0 DTD  JALZ2350_proof4.3. Classification level 3: Diseases causing PCA
Classification level 3 provides disease-level descriptions
of PCA reflecting available evidence of the underlying pa-
thology. Diagnostic criteria for PCA attributable to AD
(PCA-AD), Lewy body disease (PCA-LBD), corticobasal
degeneration (PCA-CBD), and prion disease (PCA-prion)
are described in Table 3. The definition of PCA-AD is
consistent with the IWG2 [19,36,37] definitions of AD,
which require both the presence of an appropriate clinical
phenotype and a pathophysiological biomarker consistent
with the presence of AD pathology. However,
pathophysiological biomarkers are only currently available
for AD and prion disease (although not yet incorporated
into formal diagnostic criteria for prion disease; see solid
and dashed ovals in Fig. 3). Consequently, the disease-
level descriptions provided in Table 3 are inequitable, with
attribution of an in vivo diagnosis of PCA-LBD and PCA-
CBD pending the development of suitable biomarkers. In
these cases, use of the terms probable PCA-LBD and prob-
able PCA-CBD may be appropriate where cases fulfilling
both the relevant core clinical criteria are found to be nega-
tive for AD biomarkers. As noted in Fig. 3, other disease-
level classifications may also be appropriate for individuals
with mixed or multiple pathologies (e.g., a patient with PCA
plus visual hallucinations could have LBD-variant of AD
and therefore be more appropriately labeled PCA-AD/
LBD; co-occurrence of AD and PSP: [38]) or required in
future (e.g., PCA attributable to GRN mutations; [39]).
Similarly, additional markers may become available to sup-
port existing and new classifications. Future iterations of the
PCA consensus statement must consider these issues andQ13
xtension, of IWG2’s broader category of “atypical AD”) requires fulfillment
er’s pathology (at least one of the following):
SEN2, or APP)
be appropriate.
iagnosis of PCA-LBD cannot be assigned at present. For individuals who are
shown to be AD-biomarker negative, the term probable PCA-LBD may be
-LBD would be appropriate. Other disease-level classifications may also be
/LBD).
iagnosis of PCA-CBD cannot be assigned at present. For individuals who are
e AD-biomarker negative, the term probable PCA-CBDmay be appropriate.
ld be appropriate.
l., 2014; Jackson et al., 2014; McGuire et al., 2012), but these have yet to
s of PCA-prion may be feasible. If autopsy confirmation of prion disease is
erm definite PCA-prion would be appropriate.
, cerebrospinal fluid; LBD, Lewy body disease; DLB, dementia with Lewy
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1193revise the classifications in accordance with biomarker
development and emerging clinical reports.
The division between syndrome-level and disease-level
descriptions was supported by 88% of PCAWorking Party
members surveyed who agreed with the statement
“Research criteria should discriminate the clinical syn-
drome (PCA) and the associated disease (e.g., PCA-AD,
PCA-LBD).” The discussion of the syndrome/disease issue
at consensus meetings reflected the balance sought between
developing a flexible labeling system allowing for a wide
variety of different research applications (e.g., disease-
specific trials vs. nonpharmacological interventions target-
ing cognition, behavior, or function) and avoiding
confusion by permitting a PCA subgroup (e.g., those fulfill-
ing criteria for PCA and CBS) to skew the description of
PCA. It is also important to note that the four proposed
disease-level descriptions do not have the same frequency.
Published data suggest that AD is overwhelmingly the
most common underlying cause of PCA (e.g., [14,15,31–
33,41,42]). Thus, in the absence of features to suggest an
alternative diagnosis, AD is a priori the most likely
underlying cause. The thickness of lines connecting
classification levels 2 and 3 in Fig. 3 are intended to reflect
the status of AD as the most common cause of PCA. It is
also noted that in all cases, pathological confirmation of the
underlying pathology is regarded as the “gold standard”
and assigned the prefix definite.
There are a number of research contexts in which it may
be important to identify the most likely underlying pathol-
ogy associated with the PCA syndrome. The proposed
disease-level descriptions of PCA may be of use in
disease-specific clinical trials (by providing rationale the in-
clusion of PCA subjects in AD trials), in descriptive epide-
miological studies investigating genetic and other
determinants of phenotypic heterogeneity in AD and non-
AD dementias, and in disease progression studies.1194
1195
1196
1197
1198
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12145. Further specification of PCA in a variety of research
contexts
The classification system described previously provides
syndrome-level and disease-level definitions of PCA for
use in a variety of research contexts. However, there are a
number of past and future contexts in which additional
consensus descriptors might have value. Two important sce-
narios are staging the syndrome severity and describing
phenotypic heterogeneity within PCA. In the following,
we discuss this need, alongside the current labels related to
PCA and their usage.We stop short of proposing an extended
PCA lexicon but explicate how future research might prompt
or guide a formal proposal of terms. All of the following sce-
narios consider the putative case of individuals who did, do,
or might fulfill the core PCA criteria described previously at
some point past, present, or future, plus the additional re-
quirements listed in the following.FLA 5.4.0 DTD  JALZ2350_proof6. PCA stages
One issuewhichmaymotivate an extension of PCA termi-
nology concerns how researchers describe PCA at different
stages of progression. To illustrate the issue, 11-year longitu-
dinal data are presented on an individual who came to atten-
tion as a healthy research participant but subsequently
developed PCA (see Fig. 5). The description of this patient
at different points along the disease pathway is considered
in the following alongside consideration of provisional terms.
 Prodromal/suspected/possible PCA: This term (see al-
ternatives in the following) might be ascribed (in some
circumstances, alongside other differential diagnoses)
to individuals exhibiting subtle deficits in posterior
cortical functions which are too mild or few (,3) to
fulfill the core PCA criteria mentioned previously. As
only individuals proceeding to a diagnosis of PCA
could reliably be labeled prodromal PCA, this stage
in the evolution of PCAwould most likely be identified
retrospectively in longitudinal studies (see Fig. 5). In
other situations, alternative labels such as “suspected
PCA” or “possible PCA” might be preferred. The
concept of prodromal PCA is motivated by the assump-
tion that a proportion of individuals with prodromal
AD (IWG criteria; 37; clinical symptoms present but
insufficient to affect instrumental activities of daily
living) will be in the early clinical stages of PCA. By
definition, the clinico-radiological syndrome PCA
cannot be defined at the preclinical asymptomatic at-
risk state for AD (IWG [37]) or stage 1 or 2 preclinical
AD (NIA-AA [43]) where cognitive impairment is
absent. It is also of note here that some individuals
with PCA may not ever meet NIA-AA definitions of
mild cognitive impairment (MCI), owing to the impact
of even subtle posterior cortical dysfunction on
everyday functional tasks. MCI criteria state “These
cognitive changes should be sufficiently mild that there
is no evidence of a significant impairment in social or
occupational functioning” (p. 272), and “it must be
recognized that atypical clinical presentations of AD
may arise, such as the visual variant of AD (involving
PCA) or the language variant (sometimes called logo-
penic aphasia), and these clinical profiles are also
consistent with MCI due to AD” (p. 272). However,
mild posterior cortical dysfunction can have a pro-
found impact on certain everyday functions (e.g.,
driving). Although comparing levels of “severity”
across different cognitive domains is difficult, it may
be that the relative impact of mild cognitive deficits
on everyday function may vary between typical and
atypical AD phenotypes.
 PCA: The second stage of progression might simply be
labeled PCA and could be entirely consistent with the
definition of PCA provided previously in classification
level I (namely fulfillment of the clinical, cognitive, 1 March 2017  4:01 pm  ce
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Fig. 5. Longitudinal clinical, neuropsychological, and neuroimaging profile of an individual with pathologically proven PCA-AD showing example timelines
for the provisional stages of prodromal PCA, PCA, and advanced PCA. Serial MR images (top row) show a sagittal view of the patient’s right hemisphere for all
nine visits. Repeat scans were fluid-registered to the baseline image, and color-coded voxel-compressionmaps were produced (bottom row). The scale shows the
percentage volume change per voxel (220% to 20%) with green and blue representing contraction and yellow and red representing expansion. See Kennedy
et al. [45] Q10for a more detailed case description. Abbreviations: AD, Alzheimer’s disease; MR, magnetic resonance; PCA, posterior cortical atrophy.
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1337neuroimaging, and exclusion criteria listed in Table 1).
The only point of expansion is that, just as prodromal
PCA would not necessarily equate to MCI, so PCA
would not necessarily equate to dementia. Many pa-
tients with PCA for a time only show impairment in
one of the five listed domains in McKhann et al.
([18]; i.e., evidence of visuospatial but not memory,
reasoning, language, or personality/behavior deficits).
At this stage, such cases may not fulfill the various
rules for formal classification as dementia, and there-
fore diagnosis for which dementia is a prerequisite,
namely probable AD dementia, possible AD dementia,
or possible AD dementia with evidence of the AD path-
ophysiological process.
 Advanced PCA: This third provisional staging term
could be used to describe individualswhohaveorwould
have previously met criteria for PCA but in whom dis-
ease progression has led to impairments in other aspects
of cognitive function (i.e., episodic memory, language,
executive functions, behavior, and personality).
Advanced PCA might most typically be observed in
individuals in whom either (1) visual6 nonvisual pos-
terior dysfunction with relative preservation of these
other cognitive skills was the primary complaint, but
memory, language, executive, and/or behavior/person-
ality deficits have now progressed and are also signifi-
cantly impaired or (2) impairments in visual 6
nonvisual posterior functions and one or more of these
other cognitive skills were evident at presentation but
the clinical history and/or other evidence indicate thatFLA 5.4.0 DTD  JALZ2350_proof  1posterior cortical deficits were the primary complaint
(i.e., the patient did not present/was not assessed at
the earlier stagewhenPCAcould have been diagnosed).
The term advanced PCAmight be applicable to a num-
ber of PCA patients described in the existing literature.
For example, in a study of PCA basic visual function
[44], all 21 patients fulfilled Mendez et al. [13] and
Tang-Wai et al. [14] criteria and had current or previous
evidence on formal neuropsychological assessment of
impaired visual function with relatively preserved
(normal range) scores on at least one test of episodic
memory. However, at the time of the experimental
study, 5/21 (24%) had progressed to a point where
episodic memory test scores fell below the normal
range, with 12/21 (57%) showing deficits on naming
from description (executive functions, behavior, and
personality were not assessed formally). The advanced
PCAconcept is particularly relevant to the characteriza-
tion of research participants, prognostic and longitudi-
nal studies, clinical management and care planning,
and for educating to patients and their caregivers.7. Heterogeneity within the PCA spectrum
Another issue that may motivate an extension of PCA ter-
minology is the challenge of describing the considerable het-
erogeneity that exists within the PCA spectrum. A number of
subtypes have been described previously based on the
distinct presentation of individuals or small series of patientsMarch 2017  4:01 pm  ce
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1459(e.g., [46,47]). However, other studies have suggested that
heterogeneity in PCA is best conceptualized as a
multidimensional phenotypic space rather than as a series
of distinct subtypes (see [16,44,48–50]). The Working
Party concluded that there is currently insufficient
cognitive or neuroimaging evidence to support the
existence of discrete PCA subtypes and would recommend
research to determine whether subtypes can be found in
distinct patterns of cognitive impairment, atrophy, and
disease progression. Nonetheless, the following
provisional set of qualitative descriptions of different
positions within this putative phenotypic space is provided
to encourage debate concerning the consistent labeling
among research studies and centers and to permit
individual presentations to be described or quantified in
terms of proximity to one or more of these prototypes.
 Biparietal (dorsal) variant: This subtype has been
described as “a biparietal variant defined by the pres-
ence of early, predominant, and progressive difficulty
with visuospatial function, features of Gerstmann syn-
drome, of Balint syndrome, limb apraxia, or neglect”
[19]. This IWG2 designation is broadly consistent
with other definitions of a biparietal atrophy syndrome
(e.g., [28,46,47]).
 Occipitotemporal (ventral) variant: The biparietal
variant of PCA has been contrasted with a more ventral
occipitotemporal variant defined by the presence of an
early, predominant, and progressive impairment of
visuoperceptive functions or of visual identification
of objects, symbols, words, or faces’ (IWG2:
[19,28,46,47,51]). Such a category might include
descriptions of patients with a progressive perceptual
prosopagnosia (e.g., [52]).
 Primary visual (caudal) variant: Arguably even rarer
than the biparietal or occipitotemporal syndromes is
a more caudal primary visual syndrome characterized
by primary visual failure, impairment of basic percep-
tual abilities, and bilateral occipital atrophy
[28,47,53,54]. Owing to the early damage of primary
visual cortex, as contrasted with the early
involvement of association cortices seen in the
biparietal and occipitotemporal variants, PCA
patients with this primary visual variant are most
distinct clinically and phenotypically from “typical
AD.” The primary visual variant is rarely reported
and not mentioned explicitly in IWG2. However, this
lack of evidence may partly reflect less frequent
testing/recording of basic visual functions compared
with higher order object and space processing deficits
(of which patients are also naturally more likely to
complain). An analysis of basic visual functions
(form detection, form discrimination, form
coherence, motion coherence, color discrimination,
single-point localization) found impaired performance
in at least one basic visual skill in all 21 PCA patientsFLA 5.4.0 DTD  JALZ2350_prooftested, suggesting elementary visual deficits are a more
common cause of or contributor to higher order object
and space processing problems than is typically recog-
nized [44].
 Dominant parietal variant: The presentation of visual
complaints is a core feature of both the proposed
consensus and existing single-center diagnostic
criteria. However, not all PCA patients refer explicitly
to visual problems among their primary complaints
andmay present with predominant impairment of other
posterior cortical functions, such as calculation,
spelling, and praxis [6,29,55–57]. Such presentations
are most commonly associated with biparietal
atrophy with relatively greater involvement of the
dominant/left posterior cortices (see Fig. 4). In our sur-
vey, 67% of PCAWorking Party members considered
such individuals to fall within the PCA spectrum.
This position, and the duality of the current criteria
necessitating both “Prominent early disturbance of vi-
sual6 other posterior cortical functions” and presence
of a cluster of three or more cognitive deficits which
could appear “nonvisual” (e.g., acalculia, agraphia,
and apraxia), might at first glance appear inconsistent.
However, it is important to bear in mind that there is
not a one-to-one correspondence between cognitive
tests and the underlying cognitive processes. Many
apparently “nonvisual” tasks (e.g., calculation) do
make demands on visual imagery and spatial process-
ing skills. Furthermore, as noted previously, very
detailed neuropsychological testing of patients pre-
senting with focal posterior nonvisual complaints typi-
cally uncovers evidence of subtle impairments in
visual cognition (see Fig. 4). Finally, “nonvisual” pre-
sentations are one reason why the proposed criteria
stipulate the need for a constellation of deficits (three
or more cognitive features), to exclude for example
cases of selective apraxia which could have a more
anterior basis.
Naturally, there are multiple ways of classifying clinical
heterogeneity within the PCA spectrum. An alternative
way to discriminate putative subphenotypes would be to
refer exclusively to the organization of the visual system
(e.g., ventral and dorsal streams). Certain presentations
may also merit the combination of different types of descrip-
tive terminology (e.g., prodromal occipito-temporal variant
PCA). It is anticipated that descriptions of PCA variants
may be relevant to brain-behavior studies, phenotype char-
acterization work (e.g., clarifying the degree of homogenei-
ty/heterogeneity within the PCA spectrum), and
examinations of phenotype progression (e.g., establishing
the order of loss of different aspects of cortical visual pro-
cessing). Descriptions of PCA variants may also be useful
in the design and use of nonpharmacological interventions,
aids, and strategies which are geared toward helping individ-
uals with PCA cope with or ameliorate problems associated 1 March 2017  4:01 pm  ce
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er, it should be stressed again that these descriptions are pre-
liminary characterizations of positions within a spectrum of
continuous variation.8
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15818. Conclusions
We have proposed a PCA classification framework with
both syndrome- and disease-level descriptions for use in a
number of different research contexts. The strong agreement
over the features which constitute the core clinico-
radiological syndrome (classification level 1) re-affirmed
the Working Party’s original aim of offering a consensus
statement refining and advocating specific uses and adapta-
tions of the term PCA rather than any wholesale alteration or
redescription of the syndrome. Accordingly, the working
party regard classification levels 2 (PCA-pure/PCA-plus)
and 3 (PCA-AD, PCA-LBD, PCA-CBD, PCA-Prion) as
extensions to rather than replacements for the previous
single-center diagnostic criteria, aimed at increasing the util-
ity and specification of the PCA concept in a variety of
research settings.
The three-level classification system provides a standard
against which clinicians, academics, reviewers, and editors
may evaluate and compare study populations and inclu-
sion/exclusion criteria across previous publications and
future studies. Although the proposed core features permit
of heterogeneity within the syndrome consistent with the
amassed clinical experience, reducing the variability be-
tween sites and studies caused by inconsistencies of termi-
nology and diagnostic criteria will benefit a variety of
future studies. Refining study populations and minimizing
clinico-pathological “noise” through both tighter diagnostic
criteria and in vivo biomarkers is particularly important in
the context of a relatively rare disorder such as PCA in which
sample sizes are often limited.
A number of challenges remain for the PCA research
field. A primary challenge is to understand sources and
drivers of phenotypic heterogeneity among individuals
with a common underlying pathology. For example, mem-
bers of the atypical AD PIA have contributed to the largest
analysis to date of genetic risk factors for PCA, yielding ev-
idence of both an altered risk profile across known AD risk
factors and possible novel loci some of which are associated
with visual system development [58]. The current proposed
consensus criteria for PCA may complement equivalent
consensus diagnostic criteria for typical amnestic AD
[18,19] and other atypical AD syndromes (e.g., lvPPA;
[59]) to improve the robustness and replicability of future
heterogeneity studies which may shed light on fundamental
mechanisms of disease progression and propagation.
Second, although the relationships between syndrome and
pathology are indubitably less complex than among, for
example, the frontotemporal dementias, the boundaries
between PCA, and related syndromes (e.g., CBS) requireFLA 5.4.0 DTD  JALZ2350_prooffurther clarification through quantitative investigation. For
example, motor impairment (defined by asymmetrical left
upper limb rigidity) has been found in 30% of a series of
44 patients all meeting the existing clinical criteria for PCA
[60]. Visuospatial and visuoperceptual dysfunction in CBS
patients has also been shown to predict AD pathology
[29,61,62].
Third, a further practical objective is to establish a com-
mon framework for cognitive screening, neuropsychological
examination, and selection of cognitive outcome measures
for trials involving individuals with PCA. There is a partic-
ular need for clarity regarding the evaluation of episodic
memory in PCA [63]. As noted previously, memory tests
with explicit visual demands in encoding and/or retrieval
(e.g., Rey–Osterrieth figure copy) are unsuitable. Less
obvious are the more implicit visual demands of tests such
as verbal paired associate learning that often draw on mental
imagery. Two alternate forced choice recognition memory
tests for words [64] are suitable for evaluating aspects of
episodic memory in PCA. Evaluating alternative metrics
would help optimize techniques for establishing and quanti-
fying this critical distinction between PCA and typical am-
nestic AD, namely “prominent early disturbance of vision
with relatively preserved anterograde memory.”
The proposed classification framework will not resolve
these issues directly but may improve our ability to interpret
findings across studies, increase the quality of clinical trials
for AD, and provide a foundation for future collaborative
work. There is a need to validate the reliability, sensitivity,
and specificity of the proposed criteria, particularly to estab-
lish the quantitative relationships between the different
levels of classification. The classification system will also
likely require updating and revision, particularly based on
emergence of new biomarkers and clinical evidence of
PCA attributable to non-AD and mixed pathologies.Acknowledgments
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1703RESEARCH IN CONTEXT
1. Systematic review: Consensus statements about pos-
terior cortical atrophy (PCA) were developed
through a detailed literature review, the formation
of an international multidisciplinary working party
which convened on four occasions and a Web-
based quantitative survey regarding symptom fre-
quency and the conceptualization of PCA.
2. Interpretation: The proposed classification framework
for PCA—the first consensus-based, multicenter
statement—is proposed to (1) improve the uniformity
of definition of the syndrome in a variety of research
settings, (2) encompass both syndrome- and disease-
level descriptions, (3) incorporate the recent devel-
opment of AD pathophysiological biomarkers, (4)
describe individuals with the PCA syndrome who are
negative for AD pathophysiological biomarkers, and
(5) define stages of syndrome severity and characterize
phenotypic heterogeneity within the PCA spectrum.
3. Future directions: The framework and terminology
may facilitate the interpretation of research data
across studies, be applicable across a broad range
of research scenarios (e.g., behavioral interventions,
pharmacological trials), and provide a foundation for
future collaborative work.
References
[1] Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch
Neurol 1988;45:789–93.
[2] Gr€unthal E. Zur hirnpathologischen Analyse der Alzheimerschen
Krankheit. Psychiatrische und Neurologische Wochenschr 1928;
36:401–7.FLA 5.4.0 DTD  JALZ2350_proof[3] Morel F. Les aires striee, parastriee et peristriee dans les troubles de la
fonction visuelle au cours de la maladie d’Alzheimer. Confinia Neurol
1944;6:238–42.
[4] Critchley M. The Parietal Lobes. New York: Hafner; 1953. p. 182–3.
[5] Cogan DG. Visual disturbances with focal progressive dementing dis-
ease. Am J Ophthalmol 1985;100:68–72.
[6] De Renzi E. Slowly progressive visual agnosia or apraxia without de-
mentia. Cortex 1986;22:171–80.
[7] Hof PR, Bouras C, Constandinidis J, Morrison JH. Balint’s syndrome
in Alzheimer’s disease: specific disruption of the occipito-parietal vi-
sual pathway. Brain Res 1989;493:368–75.
[8] Hof PR, Bouras C, Constantinidis J, Morrison JH. Selective disconnec-
tion of specific visual association pathways in cases of Alzheimer’s
disease presenting with Balint’s syndrome. J Neuropathol Exp Neurol
1990;49:168–84.
[9] Hof PR, Archin N, Osmand A, Dougherty J, Wells C, Bouras C, et al.
Posterior cortical atrophy in Alzheimer’s disease: analysis of a new
case and re-evaluation of a historical report. Acta neuropathologica
1993;86:215–23.
[10] Crystal HA, Horoupian DS, Katzman R, Jotkowitz S. Biopsy-proved
Alzheimer disease presenting as a right parietal lobe syndrome. Ann
Neurol 1982;12:186–8.
[11] Pick A. €Uber eine eigent€umliche Sehst€orung senil Dementer.
Jahrb€ucher f€ur Psychiatrie und Neurologie 1902;22:35.
[12] Faden MAI. Myoclonus and Alzheimer’s disease—reply. Arch Neurol
1976;33:730.
[13] Mendez MF, Ghajarania M, Perryman KM. Posterior cortical atrophy:
clinical characteristics and differences compared to Alzheimer’s dis-
ease. Dement Geriatr Cogn Disord 2002;14:33–40.
[14] Tang-Wai DF, Graff-Radford N, Boeve B, Dickson D, Parisi J,
Crook R, et al. Clinical, genetic, and neuropathologic characteristics
of posterior cortical atrophy. Neurology 2004;63:1168–74.
[15] Renner J, Burns J, Hou C, McKeel D, Storandt M, Morris J. Progres-
sive posterior cortical dysfunction: a clinicopathologic series.
Neurology 2004;63:1175–80.
[16] McMonagle P, Deering F, Berliner Y, Kertesz A. The cognitive profile
of posterior cortical atrophy. Neurology 2006;66:331–8.
[17] Kas A, de Souza LC, Samri D, Bartolomeo P, Lacomblez L, KalafatM,
et al. Neural correlates of cognitive impairment in posterior cortical at-
rophy. Brain 2011;134:1464–78.
[18] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR,
Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s dis-
ease: recommendations from the National Institute on Aging-Alz-
heimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement 2011;7:263–9.
[19] Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL,
Blennow K, et al. Advancing research diagnostic criteria for Alz-
heimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;
13:614–29.
[20] Kaeser PF, Ghika J, Borruat FX. Visual signs and symptoms in patients
with the visual variant of Alzheimer disease. BMC Ophthalmol 2015;
15:65.
[21] Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN,
Fox NC. Posterior cortical atrophy. Lancet Neurol 2012;11:170–8.
[22] Crutch SJ, Schott JM, Rabinovici GD, Boeve BF, Cappa SF,
Dickerson BC, et al. Shining a light on posterior cortical atrophy. Alz-
heimers Dement 2013;9:463–5.
[23] Crutch SJ, LehmannM,Warren JD, Rohrer JD. The language profile of
posterior cortical atrophy. J Neurol Neurosurg Psychiatry 2013;
84:460–6.
[24] Cooper SA, Murray KL, Heath CA, Will RG, Knight RS. Isolated vi-
sual symptoms at onset in sporadic Creutzfeldt-Jakob disease: the clin-
ical phenotype of the “Heidenhain variant”. Br J Ophthalmol 2005;
89:1341–2.
[25] Kropp S, Schulz-Schaeffer WJ, Finkenstaedt M, Riedemann C,
Windl O, Steinhoff BJ, et al. The Heidenhain variant of Creutzfeldt-
Jakob disease. Arch Neurol 1999;56:55–61. 1 March 2017  4:01 pm  ce
Q9
S.J. Crutch et al. / Alzheimer’s & Dementia- (2017) 1-15 15
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820[26] Caine D, Tinelli RJ, Hyare H, De Vita E, Lowe J, Lukic A, et al. The
cognitive profile of prion disease: a prospective clinical and imaging
study. Ann Clin translational Neurol 2015;2:548–58.
[27] Depaz R, Haik S, Peoc’h K, Seilhean D, Grabli D, Vicart S, et al. Long-
standing prion dementia manifesting as posterior cortical atrophy. Alz-
heimer Dis Associated Disord 2012;26:289–92.
[28] McKeith I, Dickson DW, Lowe J, EmreM, O’brien J, FeldmanH, et al.
Diagnosis and management of dementia with Lewy bodies third report
of the DLB consortium. Neurology 2005;65:1863–72.
[29] Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B,
et al. Criteria for the diagnosis of corticobasal degeneration.
Neurology 2013;80:496–503.
[30] Sha JS, Ghosh PM, Lee SE, Corbetta-Rastelli C, Jagust WJ, Kornak J,
et al. Predicting amyloid status in corticobasal syndrome using modi-
fied clinical criteria, magnetic resonance imaging and fluorodeoxyglu-
cose positron emission tomography. Alzheimers Res Ther 2015;7:8.
[31] Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, et al. Focal
cortical presentations of Alzheimer’s disease. Brain 2007;
130:2636–45.
[32] Seguin J, Formaglio M, Perret-Liaudet A, Quadrio I, Tholance Y,
Rouaud O, et al. CSF biomarkers in posterior cortical atrophy.
Neurology 2011;76:1782–8.
[33] Shakespeare TJ, Kaski D, Yong KX, Paterson RW, Slattery CF,
Ryan NS, et al. Abnormalities of fixation, saccade and pursuit in pos-
terior cortical atrophy. Brain 2015;138:1976–91.
[34] Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA,
Trojanowski JQ, et al. Comparison of analytical platforms for cerebro-
spinal fluid measures of b-amyloid 1-42, total tau, and p-tau181 for
identifying Alzheimer disease amyloid plaque pathology. Arch Neurol
2011;68:1137–44.
[35] Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P,
et al. Global standardization measurement of cerebral spinal fluid for
Alzheimer’s disease: an update from the Alzheimer’s Association
Global Biomarkers Consortium. Alzheimers Dement 2013;9:137–40.
[36] Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P,
Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s
disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 2007;
6:734–46.
[37] Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Bar-
berger-Gateau P, et al. Revising the definition of Alzheimer’s disease:
a new lexicon. Lancet Neurol 2010;9:1118–27.
[38] Dufournet B, Gautier G, Koric L, Felician O, Ceccaldi M, Guedj E,
et al. De Benson a Richardson: cooccurrence de paralysie supranucle-
aire progressive (PSP) et de maladie d’Alzheimer (MA)? Revue Neu-
rologique 2014;170:A4.
[39] Caroppo P, Belin C, Grabli D, Maillet D, De Septenville A,
Migliaccio R, et al. Posterior cortical atrophy as an extreme phenotype
of GRN mutations. JAMA Neurol 2015;72:224–8.
[40] Ossenkoppele R, Schonhaut DR, Baker SL, O’Neil JP, Janabi M,
Ghosh PM, et al. Tau, amyloid, and hypometabolism in a patient
with posterior cortical atrophy. Ann Neurol 2015;77:338–42.
[41] De Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R,
Lamari F, et al. Similar amyloid-b burden in posterior cortical atrophy
and Alzheimer’s disease. Brain 2011;134:2036–43.
[42] Rosenbloom M, Alkalay A, Agarwal N, Baker S, O’Neil J, Janabi M,
et al. Distinct clinical and metabolic deficits in PCA and AD are not
related to amyloid distribution. Neurology 2011;76:1789–96.
[43] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM,
et al. Toward defining the preclinical stages of Alzheimer’s disease:
Recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s dis-
ease. Alzheimers Dement 2011;7:280–92.FLA 5.4.0 DTD  JALZ2350_proof[44] Lehmann M, Barnes J, Ridgway GR, Wattam-Bell J, Warrington EK,
Fox NC, et al. Basic visual function and cortical thickness patterns in
posterior cortical atrophy. Cereb Cortex 2011;21:2122–32.
[45] Kennedy J, Lehmann M, Sokolska MJ, Archer H, Warrington EK,
Fox NC, et al. Visualizing the emergence of posterior cortical atrophy.
Neurocase 2012;18:248–57.
[46] Ross S, Graham N, Stuart-Green L, Prins M, Xuereb J, Patterson K,
et al. Progressive biparietal atrophy: an atypical presentation of Alz-
heimer’s disease. J Neurol Neurosurg Psychiatry 1996;61:388–95.
[47] Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical
presentations of Alzheimer’s disease: a clinical, neuropsychological,
neuroimaging and pathological study of 13 cases. Brain 2000;
123:484–98.
[48] Migliaccio R, Agosta F, Rascovsky K, Karydas A, Bonasera S,
Rabinovici G, et al. Clinical syndromes associated with posterior atro-
phy early age at onset AD spectrum. Neurology 2009;73:1571–8.
[49] Ridgway GR, Lehmann M, Barnes J, Rohrer JD, Warren JD,
Crutch SJ, et al. Early-onset Alzheimer disease clinical variants multi-
variate analyses of cortical thickness. Neurology 2012;79:80–4.
[50] Knibb JA, Woollams AM, Hodges JR, Patterson K. Making sense of
progressive non-fluent aphasia: an analysis of conversational speech.
Brain 2009;132:2734–46.
[51] Huberle E, Rupek P, Lappe M, Karnath HO. Perception of biological
motion in visual agnosia. Front Behav Neurosci 2012;6:56.
[52] Grossi D, Soricelli A, Ponari M, Salvatore E, Quarantelli M,
Prinster A, et al. Structural connectivity in a single case of progressive
prosopagnosia: the role of the right inferior longitudinal fasciculus.
Cortex 2014;56:111–20.
[53] Chan D, Crutch S,Warrington E. A disorder of colour perception asso-
ciated with abnormal colour after-images: a defect of the primary vi-
sual cortex. J Neurol Neurosurg Psychiatry 2001;71:515–7.
[54] Levine DN, Lee JM, Fisher C. The visual variant of Alzheimer’s dis-
ease: a clinicopathologic case study. Neurology 1993;43:305–13.
[55] Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y,
Gibbons L, et al. Cognitive phenotypes in Alzheimer’s disease and ge-
netic risk. Cortex 2007;43:835–45.
[56] Aharon-Peretz J, Israel O, Goldsher D, Peretz A. Posterior cortical at-
rophy variants of Alzheimer’s disease. Demen Geriatr Cogn Disord
1999;10:483–7.
[57] Green RC, Goldstein F, Mirra S, Alazraki N, Baxt J, Bakay R. Slowly
progressive apraxia in Alzheimer’s disease. J Neurol Neurosurg Psy-
chiatry 1995;59:312–5.
[58] Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ,
Ryan NS, et al. Genetic risk factors for the posterior cortical atrophy
variant of Alzheimer’s disease. Alzheimers Dement 2016;12:862–71.
[59] Gorno-Tempini M, Hillis A, Weintraub S, Kertesz A, Mendez M,
Cappa SF, et al. Classification of primary progressive aphasia and its
variants. Neurology 2011;76:1006–14.
[60] Ryan NS, Shakespeare TJ, LehmannM, Keihaninejad S, Nicholas JM,
Leung KK, et al. Motor features in posterior cortical atrophy and their
imaging correlates. Neurobiol Aging 2014;35:2845–57.
[61] Boyd CD, Tierney M, Wassermann EM, Spina S, Oblak AL, Ghetti B,
et al. Visuoperception test predicts pathologic diagnosis of Alzheimer
disease in corticobasal syndrome. Neurology 2014;83:510–9.
[62] Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW,
DeArmond SJ, et al. Clinicopathological correlations in corticobasal
degeneration. Ann Neurol 2011;70:327–40.
[63] Ahmed S, Baker I, Husain M, Thompson S, Kipps C, Hornberger M,
et al. Memory impairment at initial clinical presentation in posterior
cortical atrophy. J Alzheimers Dis 2016;52:1245–50.
[64] Warrington EK. The Camden Memory Tests Manual. Hove: Psychol-
ogy Press; 1996. 1 March 2017  4:01 pm  ce
1821
1822
1823
1824
1825
